Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.52 |
| ▸ | PKM | P14618 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | ITGB1 | P05556 | 4/20 | 0.50 |
| ▸ | ITGA4 | P13612 | 4/20 | 0.50 |
| ▸ | FAP | Q12884 | 1/20 | 0.49 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.48 |
| ▸ | LTA4H | P09960 | 1/20 | 0.48 |
| ▸ | FKBP1A | P62942 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | PPID | Q08752 | 1/20 | 0.47 |
| ▸ | PRCP | P42785 | 1/20 | 0.47 |
| ▸ | F2 | P00734 | 1/20 | 0.47 |
| ▸ | NPC1 | O15118 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2180711 | 1.00 | CYP3A4 (0.52) | CYP3A4CYP2C9PKMCYP2C19ITGB1 | |
| SCHEMBL23659223 | 1.00 | CYP3A4 (0.52) | CYP3A4CYP2C9PKMCYP2C19ITGB1 | |
| SCHEMBL9545364 | 0.88 | FKBP1A (0.55) | CYP3A4CYP2C9PKMCYP2C19L3MBTL1 | |
| SCHEMBL194738 | 0.85 | ITGB1 (0.53) | CYP3A4CYP2C9PKMCYP2C19ITGB1 | |
| SCHEMBL6351617 | 0.85 | ITGB1 (0.53) | CYP3A4CYP2C9PKMCYP2C19ITGB1 | |
| SCHEMBL10456661 | 0.85 | PRCP (0.61) | CYP3A4CYP2C9L3MBTL1SMN1; SMN2TSHR | |
| SCHEMBL6354036 | 0.84 | CYP3A4 (0.51) | CYP3A4CYP2C9PKMCYP2C19ITGB1 | |
| SCHEMBL6357029 | 0.84 | ALDH1A1 (0.52) | CYP3A4CYP2C9PKMCYP2C19FAP | |
| SCHEMBL6351647 | 0.83 | CYP3A4 (0.52) | CYP3A4CYP2C9PKMCYP2C19ITGB1 | |
| SCHEMBL9545156 | 0.83 | ALDH1A1 (0.51) | CYP3A4CYP2C9PKMCYP2C19ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 182 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4633638-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | Luminous Mind Inc. (US) | 2025-10-22 | — | — | EP | claimed |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. | 2025-05-22 | — | — | US | claimed |
| US-20250152601-A1 | Compositions and Methods for the Treatment of Sexual Dysfunctions | THE JONATHAN HURT LIVING TRUST (US) | 2025-05-15 | — | — | US | claimed |
| WO-2024130044-A1 | TREATMENT OF PSYCHOLOGICAL FACTORS AFFECTING OTHER MEDICAL CONDITIONS (PFAOMC) | LUMINOUS MIND INC. (US) | 2024-06-20 | — | — | WO | claimed |
| US-20240043473-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | PHOENIX NEST INC. | 2024-02-08 | — | — | US | claimed |
| CN-113382719-B | Compositions for delivering therapeutic agents, methods of use and methods of preparation thereof | 迪斯拉普申实验室公司 | 2023-10-31 | — | — | CN | claimed |
| WO-2023154450-A2 | (AMPA-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GILGAMESH PHARMACEUTICALS, INC. (US) | 2023-08-17 | — | — | WO | claimed |
| US-20230157976-A1 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | THERMOLIFE INTERNATIONAL, LLC | 2023-05-25 | — | — | US | claimed |
| US-11612583-B2 | Disease modifying methods for treating neurodegenerative diseases using nootropic agents | NEVADA RESEARCH & INNOVATION CORPORATION (US) | 2023-03-28 | — | — | US | claimed |
| US-20230039272-A1 | COMPOSITION FOR IMPROVED ENERGY, FOCUS AND CLARITY | GWELLA MUSHROOMS INC (CA) | 2023-02-09 | — | — | US | claimed |
| US-11541020-B2 | Hexylamine salts and methods of using hexylamine | THERMOLIFE INTERNATIONAL, LLC (US) | 2023-01-03 | — | — | US | claimed |
| WO-2022173827-A1 | NOOTROPIC PEPTIDES FOR TREATING LYSOSOMAL STORAGE DISEASES | PHOENIX NEST INC. (US) | 2022-08-18 | — | — | WO | claimed |
| US-20220184030-A1 | N-Phenylacetyl-L-prolylglycine ethyl ester compositions and methods for using the same | THOMPSON CHRISTOPHER (US) | 2022-06-16 | — | — | US | claimed |
| US-20200215149-A1 | N-Phenylacetyl-L-prolylglycine ethyl ester compositions and methods for using the same | THOMPSON CHRISTOPHER DAVID (US) | 2020-07-09 | — | — | US | claimed |
| WO-2017049162-A1 | COMPOSITIONS FOR PROVIDING AGENTS THAT DEGRADE IN WATER | VIRUN, INC. (US) | 2017-03-23 | — | — | WO | claimed |
| CN-104788352-A | Preparation methods of N-phenylacetyl-L-proline, and N-(1-(phenylacetyl)-L-prolyl)glycine ethyl ester | SHANGHAI XUXIN CHEMICAL CO LTD | 2015-07-22 | — | — | CN | claimed |
| US-12616695-B2 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases | METRIOPHARM AG (CH) | 2026-05-05 | — | — | US | disclosed |
| US-20260102340-A1 | Therapeutic Formulation | 1000739373 ONTARIO LTD (CA) | 2026-04-16 | — | — | US | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | BRAINCELLS, INC (US) | 2007-10-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230039272-A1 | COMPOSITION FOR IMPROVED ENERGY, FOCUS AND CLARITY | ADORA2A, BHMT, METTL3 | CYP3A4 2123/4885CYP2C9 4137/4885PKM 1004/4885 |
| US-11541020-B2 | Hexylamine salts and methods of using hexylamine | SLC6A2, CPT1B, GYS1 | CYP3A4 801/4885CYP2C9 536/4885PKM 344/4885 |
| US-20260102340-A1 | Therapeutic Formulation | MTNR1A, CHRM3, MC3R | CYP3A4 862/4885CYP2C9 792/4885PKM 2996/4885 |
| US-20070244143-A1 | MODULATION OF NEUROGENESIS BY NOOTROPIC AGENTS | GAP43, BDNF, DCX | CYP3A4 4880/4885CYP2C9 4882/4885PKM 2948/4885 |
| US-20230157976-A1 | HEXYLAMINE SALTS AND METHODS OF USING HEXYLAMINE | SLC6A2, CPT1B, GYS1 | CYP3A4 801/4885CYP2C9 536/4885PKM 344/4885 |
| US-12616695-B2 | Use of 5-amino-2,3-dihydro-1,4-phthalazinedione in the treatment of rare chronic inflammatory pulmonary diseases | CRYZ, PDE12, FKBP5 | CYP3A4 3314/4885CYP2C9 4221/4885PKM 4162/4885 |
| US-20250161264-A1 | (AMPAR-PAM)-NMDA RECEPTOR ANTAGONIST COMBINATION THERAPY FOR TREATMENT OF MENTAL CONDITIONS AND DISORDERS | GRIN2A, GRIN1, GRIN3A | CYP3A4 2491/4885CYP2C9 2895/4885PKM 299/4885 |
| US-11612583-B2 | Disease modifying methods for treating neurodegenerative diseases using nootropic agents | INA, BDNF, GAP43 | CYP3A4 4613/4885CYP2C9 4858/4885PKM 770/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.